Research ExplorerPublicationsThe European landscape on allogeneic haematopoietic cell tra...

The European landscape on allogeneic haematopoietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: A perspective from the Chronic Malignancies Working Party of the EBMT

Standard

The European landscape on allogeneic haematopoietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: A perspective from the Chronic Malignancies Working Party of the EBMT. / Tournilhac, Olivier; van Gelder, Michel; Eikema, Dirk-Jan; Zinger, Nienke; Dreger, Peter; Bornhäuser, Martin; Vucinic, Vladan; Scheid, Christof; Cornelissen, Jan J; Schroeder, Thomas; Jindra, Pavel; Sengeloev, Henrik; Nguyen Quoc, Stephanie; Stelljes, Matthias; Blau, Igor Wolfgang; Mayer, Jiri; Paneesha, Shankara; Chevallier, Patrice; Forcade, Edouard; Kröger, Nicolaus; Blaise, Didier; Gribben, John; Nielsen, Bendt; Johansson, Jan-Erik; Kyriakou, Charalampia; Beguin, Yves; Pioltelli, Pietro; Sampol, Antònia; McLornan, Donal P; Schetelig, Johannes; Hayden, Patrick J; Yakoub-Agha, Ibrahim.

In: BONE MARROW TRANSPL, Vol. 58, No. 6, 06.2023, p. 621-624.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Tournilhac, O, van Gelder, M, Eikema, D-J, Zinger, N, Dreger, P, Bornhäuser, M, Vucinic, V, Scheid, C, Cornelissen, JJ, Schroeder, T, Jindra, P, Sengeloev, H, Nguyen Quoc, S, Stelljes, M, Blau, IW, Mayer, J, Paneesha, S, Chevallier, P, Forcade, E, Kröger, N, Blaise, D, Gribben, J, Nielsen, B, Johansson, J-E, Kyriakou, C, Beguin, Y, Pioltelli, P, Sampol, A, McLornan, DP, Schetelig, J, Hayden, PJ & Yakoub-Agha, I 2023, 'The European landscape on allogeneic haematopoietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: A perspective from the Chronic Malignancies Working Party of the EBMT', BONE MARROW TRANSPL, vol. 58, no. 6, pp. 621-624. https://doi.org/10.1038/s41409-023-01955-z

APA

Tournilhac, O., van Gelder, M., Eikema, D-J., Zinger, N., Dreger, P., Bornhäuser, M., Vucinic, V., Scheid, C., Cornelissen, J. J., Schroeder, T., Jindra, P., Sengeloev, H., Nguyen Quoc, S., Stelljes, M., Blau, I. W., Mayer, J., Paneesha, S., Chevallier, P., Forcade, E., ... Yakoub-Agha, I. (2023). The European landscape on allogeneic haematopoietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: A perspective from the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPL, 58(6), 621-624. https://doi.org/10.1038/s41409-023-01955-z

Vancouver

Tournilhac O, van Gelder M, Eikema D-J, Zinger N, Dreger P, Bornhäuser M et al. The European landscape on allogeneic haematopoietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: A perspective from the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPL. 2023 Jun;58(6):621-624. https://doi.org/10.1038/s41409-023-01955-z

Bibtex

@article{5b4dd05d21bc4fa9ac497c27140b1cab,
title = "The European landscape on allogeneic haematopoietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: A perspective from the Chronic Malignancies Working Party of the EBMT",
abstract = "Allogeneic transplantation (allo-HCT) is a curative treatment in CLL whose efficacy including the most severe forms had led to the 2006 EBMT recommendations. The advent after 2014 of targeted therapies has revolutionized CLL management, allowing prolonged control to patients who have failed immunochemotherapy and/or have TP53 alterations. We analysed the pre COVID pandemic 2009-2019 EBMT registry. The yearly number of allo-HCT raised to 458 in 2011 yet dropped from 2013 onwards to an apparent plateau above 100. Within the 10 countries who were under the EMA for drug approval and performed 83.5% of those procedures, large initial differences were found but the annual number converged to 2-3 per 10 million inhabitants during the 3 most recent years suggesting that allo-HCT remains applied in selected patients. Long-term follow-up on targeted therapies shows that most patients relapse, some early, with risk factors and resistance mechanisms being described. The treatment of patients exposed to both BCL2 and BTK inhibitors and especially those with double refractory disease will become a challenge in which allo-HCT remains a solid option in competition with emerging therapies that have yet to demonstrate their long-term effectiveness.",
keywords = "Humans, Leukemia, Lymphocytic, Chronic, B-Cell/therapy, Hematopoietic Stem Cell Transplantation/methods, Neoplasm Recurrence, Local, COVID-19/etiology, Transplantation, Homologous/methods, Transplantation Conditioning/methods, Retrospective Studies",
author = "Olivier Tournilhac and {van Gelder}, Michel and Dirk-Jan Eikema and Nienke Zinger and Peter Dreger and Martin Bornh{\"a}user and Vladan Vucinic and Christof Scheid and Cornelissen, {Jan J} and Thomas Schroeder and Pavel Jindra and Henrik Sengeloev and {Nguyen Quoc}, Stephanie and Matthias Stelljes and Blau, {Igor Wolfgang} and Jiri Mayer and Shankara Paneesha and Patrice Chevallier and Edouard Forcade and Nicolaus Kr{\"o}ger and Didier Blaise and John Gribben and Bendt Nielsen and Jan-Erik Johansson and Charalampia Kyriakou and Yves Beguin and Pietro Pioltelli and Ant{\`o}nia Sampol and McLornan, {Donal P} and Johannes Schetelig and Hayden, {Patrick J} and Ibrahim Yakoub-Agha",
note = "{\textcopyright} 2023. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2023",
month = jun,
doi = "10.1038/s41409-023-01955-z",
language = "English",
volume = "58",
pages = "621--624",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "6",

}

RIS

TY - JOUR

T1 - The European landscape on allogeneic haematopoietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: A perspective from the Chronic Malignancies Working Party of the EBMT

AU - Tournilhac, Olivier

AU - van Gelder, Michel

AU - Eikema, Dirk-Jan

AU - Zinger, Nienke

AU - Dreger, Peter

AU - Bornhäuser, Martin

AU - Vucinic, Vladan

AU - Scheid, Christof

AU - Cornelissen, Jan J

AU - Schroeder, Thomas

AU - Jindra, Pavel

AU - Sengeloev, Henrik

AU - Nguyen Quoc, Stephanie

AU - Stelljes, Matthias

AU - Blau, Igor Wolfgang

AU - Mayer, Jiri

AU - Paneesha, Shankara

AU - Chevallier, Patrice

AU - Forcade, Edouard

AU - Kröger, Nicolaus

AU - Blaise, Didier

AU - Gribben, John

AU - Nielsen, Bendt

AU - Johansson, Jan-Erik

AU - Kyriakou, Charalampia

AU - Beguin, Yves

AU - Pioltelli, Pietro

AU - Sampol, Antònia

AU - McLornan, Donal P

AU - Schetelig, Johannes

AU - Hayden, Patrick J

AU - Yakoub-Agha, Ibrahim

N1 - © 2023. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2023/6

Y1 - 2023/6

N2 - Allogeneic transplantation (allo-HCT) is a curative treatment in CLL whose efficacy including the most severe forms had led to the 2006 EBMT recommendations. The advent after 2014 of targeted therapies has revolutionized CLL management, allowing prolonged control to patients who have failed immunochemotherapy and/or have TP53 alterations. We analysed the pre COVID pandemic 2009-2019 EBMT registry. The yearly number of allo-HCT raised to 458 in 2011 yet dropped from 2013 onwards to an apparent plateau above 100. Within the 10 countries who were under the EMA for drug approval and performed 83.5% of those procedures, large initial differences were found but the annual number converged to 2-3 per 10 million inhabitants during the 3 most recent years suggesting that allo-HCT remains applied in selected patients. Long-term follow-up on targeted therapies shows that most patients relapse, some early, with risk factors and resistance mechanisms being described. The treatment of patients exposed to both BCL2 and BTK inhibitors and especially those with double refractory disease will become a challenge in which allo-HCT remains a solid option in competition with emerging therapies that have yet to demonstrate their long-term effectiveness.

AB - Allogeneic transplantation (allo-HCT) is a curative treatment in CLL whose efficacy including the most severe forms had led to the 2006 EBMT recommendations. The advent after 2014 of targeted therapies has revolutionized CLL management, allowing prolonged control to patients who have failed immunochemotherapy and/or have TP53 alterations. We analysed the pre COVID pandemic 2009-2019 EBMT registry. The yearly number of allo-HCT raised to 458 in 2011 yet dropped from 2013 onwards to an apparent plateau above 100. Within the 10 countries who were under the EMA for drug approval and performed 83.5% of those procedures, large initial differences were found but the annual number converged to 2-3 per 10 million inhabitants during the 3 most recent years suggesting that allo-HCT remains applied in selected patients. Long-term follow-up on targeted therapies shows that most patients relapse, some early, with risk factors and resistance mechanisms being described. The treatment of patients exposed to both BCL2 and BTK inhibitors and especially those with double refractory disease will become a challenge in which allo-HCT remains a solid option in competition with emerging therapies that have yet to demonstrate their long-term effectiveness.

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell/therapy

KW - Hematopoietic Stem Cell Transplantation/methods

KW - Neoplasm Recurrence, Local

KW - COVID-19/etiology

KW - Transplantation, Homologous/methods

KW - Transplantation Conditioning/methods

KW - Retrospective Studies

U2 - 10.1038/s41409-023-01955-z

DO - 10.1038/s41409-023-01955-z

M3 - SCORING: Review article

C2 - 36977926

VL - 58

SP - 621

EP - 624

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 6

ER -